Finance

Lists
Why is PTGX down 2.55%?
Dive Deeper
PTGX:NASDAQ
Protagonist Therapeutics Inc
$130.95
-2.55%
(-3.43) 1D
$130.95
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PTGX...
Open
$134.03
High
$134.90
Low
$130.64
Mkt. cap
8.55B
Avg. vol.
698.66K
Volume
759.92K
P/E ratio
27.74
52-wk high
$160.81
52-wk low
$77.00
EPS
$4.72
Beta
1.21
Shares outstanding
65.27M
No. of employees
149
Open
$134.03
High
$134.90
Low
$130.64
Mkt. cap
8.55B
Avg. vol.
698.66K
Volume
759.92K
P/E ratio
27.74
52-wk high
$160.81
52-wk low
$77.00
EPS
$4.72
Beta
1.21
Shares outstanding
65.27M
No. of employees
149
News stories
From web sources and news partners
About Protagonist Therapeutics Inc
CEO-
Employees149
Founded2006
HeadquartersNewark, California, United States
SectorHealth Care
IndustryBiotechnology
Websiteprotagonist-inc.com
Analyst ratings
Based on 13 analysts giving stock ratings to PTGX in the past 3 months
Strong buy
Buy
13
Hold
0
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for PTGX in the last 3 months.
Highest
Current $130.95
$221.00 (+68.77%)
Average
$180.00 (+37.46%)
Lowest
$151.00 (+15.31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Evan Seigerman
BMO Capital
Buy
Maintained
$190.00
+45.1%
11/09/2026
Alice Nettleton
UBS
Buy
Maintained
$184.00
+40.5%
11/10/2026
Yun Zhong
Wedbush
Buy
Maintained
$173.00
+32.1%
11/09/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
$151.00
+15.3%
11/09/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$221.00
+68.8%
11/06/2026
Etzer Darout
Barclays
Buy
Maintained
$180.00
+37.5%
11/06/2026
Tara Bancroft
TD Cowen
Buy
Reiterated
$160.00
+22.2%
10/21/2026
Geoff Meacham
Citi
Buy
Maintained
$182.00
+39%
10/15/2026
Will Soghikian
Leerink Partners
Buy
Initiated
$190.00
+45.1%
10/12/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$190.00
+45.1%
10/12/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
$186.00
+42%
08/31/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
09/01/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$173.00
+32.1%
08/31/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$170.00
+29.8%
08/31/2026
Unknown Analyst
Jefferies
Buy
Maintained
$121.00
-7.6%
07/16/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
7.44M
56.37M
213.48M
274.41M
Cost of goods sold
-
-
-
1.10M
Cost of revenue
-
-
-
1.10M
Research and development expenses
46.36M
46.74M
42.06M
41.27M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.43M
13.28M
12.65M
13.70M
Operating expense
57.79M
60.02M
54.71M
54.98M
Total operating expenses
57.79M
60.02M
54.71M
56.08M
Operating income
-50.36M
-3.65M
158.77M
218.33M
Other non operating income
27.00K
53.00K
-81.00K
-14.00K
EBT including unusual items
-43.72M
2.28M
165.11M
226.57M
EBT excluding unusual items
-43.72M
2.28M
165.11M
226.57M
Income tax expense
666.00K
-1.50M
2.26M
6.56M
Effective tax rate
-1.52%
-65.85%
1.37%
2.89%
Other operating expenses
-
-
-
-
Net income
-44.38M
3.78M
162.85M
220.02M
Net profit margin
-596.80%
6.71%
76.28%
80.18%
Earnings per share
-0.69
0.05
2.29
3.07
Interest and investment income
6.76M
5.88M
6.43M
8.25M
Interest expense
-
-
-
-
Net interest expenses
6.76M
5.88M
6.43M
8.25M
Depreciation and amortization charges
-
-
-
-
EBITDA
-49.98M
-3.24M
159.16M
218.74M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps